Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue SUPPL. 1, 2011, Pages

  Freudenberg, Lutz S ^a   Jentzen, Walter ^a   Stahl, Alexander ^a   Bockisch, Andreas ^a   Rosenbaum Krumme, Sandra J ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Computed tomography; Differentiated thyroid carcinoma; Dosimetry; Iodine 124; Iodine 131; Positron emission tomography; Radioiodine

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 124; IODINE 131; RECOMBINANT THYROTROPIN; THYROID HORMONE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DOSIMETRY; DRUG HALF LIFE; HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; RADIOSENSITIVITY; REVIEW; SALIVARY GLAND; THERAPY EFFECT; THYROID CARCINOMA; WHOLE BODY SCINTISCANNING; ADENOCARCINOMA; CANCER STAGING; FORECASTING; METHODOLOGY; PATHOLOGY; RADIATION DOSE; RADIOGRAPHY; RADIOMETRY; SCINTISCANNING; THYROID TUMOR;

ADENOCARCINOMA; FLUORODEOXYGLUCOSE F18; FORECASTING; HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79957942593     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1773-5     Document Type: Review

References (67)

1. RJ Robbins MJ Schlumberger 2005 The evolving role of 131I for the treatment of differentiated thyroid carcinoma J Nucl Med 46 28S 37S 15653649 1:CAS:528:DC%2BD2MXhsVeksLw%3D (Pubitemid 47619016)
2. B Riemann JA Krämer KW Schmid H Dralle M Dietlein H Schicha, et al. 2010 Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial Nuklearmedizin 49 3 79 84 20505894 10.3413/nukmed-0302
3. M Biermann M Pixberg B Riemann A Schuck A Heinecke KW Schmid, et al. 2009 Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer - results after 874 patient-years of follow-up in the MSDS-trial Nuklearmedizin 48 3 89 98 19322503
4. FA Verburg B de Keizer JM de Klerk EG Lentjes CJ Lips JW van Isselt 2009 Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection Nuklearmedizin 48 1 26 29 19212608 1:CAS:528: DC%2BD1MXksVOqtr8%3D
5. R Benua N Cicale M Sonenberg, et al. 1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer AJR Am J Roentgenol 87 171 179 1:STN:280:DyaF38%2FgvVKktg%3D%3D
6. AM Sawka K Thephamongkhol M Brouwers H Thebane G Browman HG Gerstein 2004 A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer J Clin Endocrinol Metab 89 3668 3676 15292285 10.1210/jc.2003-031167 1:CAS:528:DC%2BD2cXmslKmsbc%3D (Pubitemid 39089119)
7. HR Maxon EE Englaro SR Thomas, et al. 1992 Radioiodine-131 therapy for well differentiated thyroid cancer: a quantitative radiation dosimetric approach - outcome and validation in 85 patients J Nucl Med 33 1132 1116 1597728
8. HR Maxon SR Thomas VS Hertzberg, et al. 1983 Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer N Engl J Med 309 937 941 6621620 10.1056/NEJM198310203091601 1:STN:280: DyaL2c%2Fhtl2nug%3D%3D (Pubitemid 13008961)
9. HR Maxon SR Thomas RC Samaratunga 1997 Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer Thyroid 7 183 187 9133681 10.1089/thy.1997.7.183 1:STN:280:DyaK2s3nvFWksQ%3D%3D (Pubitemid 27190577)
10. B Kimmig HJ Hermann 1983 Measurement of dose during radioiodine treatment of thyroid cancer Acta Endocrinol 252 Suppl 72
11. M Dietlein J Dressler F Farahati, et al. 2004 Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2) Nuklearmedizin 43 115 120 15316577 1:STN:280:DC%2BD2cvhtFymtg%3D%3D (Pubitemid 39121134)
12. EL Mazzaferri 1999 An overview of the management of papillary and follicular thyroid carcinoma Thyroid 9 5 421 427 10365671 10.1089/thy.1999.9.421 1:STN:280:DyaK1M3ptFOqsQ%3D%3D (Pubitemid 29244917)
13. R Dorn J Kopp H Vogt, et al. 2003 Dosimetry guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach J Nucl Med 44 451 456 12621014 1:CAS:528:DC%2BD3sXislKnur4%3D (Pubitemid 39586024)
14. EE Furhang SM Larson P Buranapong, et al. 1999 Thyroid cancer dosimetry using clearance fitting J Nucl Med 40 131 136 9935068 1:STN:280: DyaK1M7jtFOltQ%3D%3D (Pubitemid 29044183)
15. M Lassmann C Reiners M Luster 2010 Dosimetry and thyroid cancer: the individual dosage of radioiodine Endocr Relat Cancer 17 3 R161 R172 20448022 10.1677/ERC-10-0071 1:CAS:528:DC%2BC3cXht1KqsLrP
16. FA Verburg RB Verkooijen MP Stokkel JW van Isselt 2009 The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I Nuklearmedizin 48 4 138 142 19384451 1:STN:280:DC%2BD1MrjtVGltQ%3D%3D
17. MA Flower VR McCready 1997 Radionuclide therapy dose calculations: what accuracy can be achieved Eur J Nucl Med 24 1462 9391179 10.1007/s002590050174 1:STN:280:DyaK1c%2FlsVWktw%3D%3D (Pubitemid 28000020)
18. AF Phillips JL Haybittle GR Newberry 1960 Use of iodine-124 for the treatment of carcinoma of the thyroid Acta Unio Int Contra Cancrum 16 1434 1438 14432601 1:CAS:528:DyaF3MXhtlOnug%3D%3D
19. YE Erdi H Macapinlac SM Larson, et al. 1999 Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging Clin Positron Imaging 2 41 46 14516552 10.1016/S1095-0397(99)00004-7
20. KS Pentlow MC Graham RM Lambrecht, et al. 1996 Quantitative imaging of iodine-124 with PET J Nucl Med 37 1557 1562 8790218 1:CAS:528:DyaK28XlvF2mtrg%3D (Pubitemid 26321647)
21. KS Pentlow MC Graham RM Lambrecht, et al. 1991 Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy Med Phys 18 357 366 1870476 10.1118/1.596728 1:STN:280:DyaK3MzjtlCmsA%3D%3D
22. LS Freudenberg G Antoch J Knust R Görges SP Müller A Bockisch, et al. 2004 Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer Eur Radiol 14 2092 2098 15232708 10.1007/s00330-004-2350-0 1:STN:280:DC%2BD2crjtVGmtw%3D%3D (Pubitemid 39481183)
23. W Jentzen L Freudenberg EG Eising W Sonnenschein J Knust A Bockisch 2008 Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer J Nucl Med 49 6 1017 1023 18483099 10.2967/jnumed.107.047159 (Pubitemid 351793444)
24. DC Crawford MA Flower BE Pratt, et al. 1997 Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography Eur J Nucl Med 24 1470 1478 9391181 10.1007/s002590050176 1:STN:280:DyaK1c%2FlsVWktQ%3D%3D (Pubitemid 28000022)
25. Freudenberg LS, Bockisch A, Jentzen W. 124I positron emission tomographic dosimetry and positron emission tomography/computed tomography imaging in differentiated thyroid cancer. In: Biersack HJ, Grünwald F, editors. Thyroid cancer. 2nd ed. Berlin: Springer; 2005.
26. P Frey D Townsend A Flattet, et al. 1986 Tomographic imaging of the human thyroid using I-124 J Clin Endocrinol Metab 63 918 927 3488999 10.1210/jcem-63-4-918 1:STN:280:DyaL28zgsVynuw%3D%3D (Pubitemid 16004296)
27. P Frey D Townsend A Jeavons, et al. 1985 In vivo imaging of the human thyroid with a positron camera using 124I Eur J Nucl Med 10 472 476 3874064 10.1007/BF00256597 1:STN:280:DyaL2M3jtVOmtw%3D%3D (Pubitemid 15117792)
28. RM Lambrecht N Woodhouse R Phillips, et al. 1988 Investigational study of iodine-124 with a positron camera Am J Physiol Imaging 3 197 200 3265064 1:STN:280:DyaL1M7gsFCmug%3D%3D (Pubitemid 19047802)
29. G Sgouros K Kolbert A Sheikh, et al. 2004 Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software J Nucl Med 45 1366 1372 15299063 1:CAS:528:DC%2BD2cXnsFSmu70%3D (Pubitemid 47618537)
30. LS Freudenberg W Jentzen T Petrich C Frömke RJ Marlowe T Heusner, et al. 2010 Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons Eur J Nucl Med Mol Imaging 37 2267 2276 20661558 10.1007/s00259-010-1565-3 1:CAS:528:DC%2BC3cXhtl2isrjE
31. W Jentzen 2010 Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging Phys Med Biol 55 8 2365 2398 20360631 10.1088/0031-9155/55/8/016
32. LS Freudenberg C Frömke T Petrich RJ Marlowe WW Koska W Brandau, et al. 2010 Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer Exp Clin Endocrinol Diabetes 118 7 393 399 19856257 10.1055/s-0029-1225350 1:CAS:528:DC%2BC3cXhtVeisL%2FM
33. AR Stahl L Freudenberg A Bockisch W Jentzen 2009 A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma Eur J Nucl Med Mol Imaging 36 7 1147 1155 19247651 10.1007/s00259-009-1077-1 1:CAS:528:DC%2BD1MXmvV2rur0%3D
34. ME O'Connell MA Flower PJ Hinton, et al. 1993 Radiation dose assessment in radioiodine therapy: dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET Radiother Oncol 28 16 26 8234866 10.1016/0167-8140(93)90180-G (Pubitemid 23286136)
35. LS Freudenberg W Jentzen R Görges T Petrich RJ Marlowe J Knust, et al. 2007 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact Nuklearmedizin 46 4 121 128 17690789 1:CAS:528: DC%2BD2sXhtFaht7rK (Pubitemid 47356534)
36. EJ Knust K Dutschka R Weinreich 2000 Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets Appl Radiat Isot 52 181 184 10697724 10.1016/S0969-8043(99)00127-X 1:CAS:528:DC%2BD3cXhtlCju7w%3D
37. W Jentzen L Freudenberg A Bockisch 2011 Quantitative imaging of 124I with PET/CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections Q J Nucl Med Mol Imaging 55 21 43 21386783 1:STN:280:DC%2BC3M3ltFChsg%3D%3D
38. W Jentzen R Weise J Kupferschläger L Freudenberg W Brandau R Bares, et al. 2008 Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems Eur J Nucl Med Mol Imaging 35 3 611 623 17929014 10.1007/s00259-007-0554-7 (Pubitemid 351661669)
39. SM Eschmann G Reischl K Bilger, et al. 2002 Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET Eur J Nucl Med 29 760 767 10.1007/s00259-002-0775-8 1:CAS:528:DC%2BD38XlvVWnu7k%3D
40. A Bockisch L Freudenberg S Rosenbaum W Jentzen 2006 (124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution Eur J Nucl Med Mol Imaging 33 11 1247 1248 16909225 10.1007/s00259-006-0208-1 (Pubitemid 44630777)
41. L Chen Q Luo Y Shen Y Yu Z Yuan H Lu, et al. 2008 Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma J Nucl Med 49 12 1952 1957 18997044 10.2967/jnumed.108.052399
42. KK Wong N Zarzhevsky JM Cahill KA Frey AM Avram 2009 Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma Br J Radiol 82 982 860 876 19433487 10.1259/bjr/25645894 1:STN:280:DC%2BD1MnislCntw%3D%3D
43. HT Phan PL Jager AM Paans JT Plukker MG Sturkenboom WJ Sluiter, et al. 2008 The diagnostic value of 124I-PET in patients with differentiated thyroid cancer Eur J Nucl Med Mol Imaging 35 5 958 965 18175115 10.1007/s00259-007-0660- 6
44. F Capoccetti B Criscuoli G Rossi F Ferretti C Manni E Brianzoni 2009 The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer Q J Nucl Med Mol Imaging 53 5 536 545 19910907 1:STN:280:DC%2BD1MjlvFyntg%3D%3D
45. Fleming ID, Cooper JS, Henson DE. AJCC cancer staging manual. 5th ed. American Joint Committee on Cancer: Lippincott-Raven, Philadelphia;1997
46. D Van Nostrand S Moreau VV Bandaru F Atkins S Chennupati M Mete, et al. 2010 (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer Thyroid 20 8 879 883 20615132 10.1089/thy.2009.0430
47. LS Freudenberg G Antoch A Frilling W Jentzen SJ Rosenbaum H Kühl, et al. 2008 Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET Eur J Nucl Med Mol Imaging 35 5 950 957 18193222 10.1007/s00259-007-0634-8 1:CAS:528:DC%2BD1cXkvVyjur0%3D
48. T Leitha A Staudenherz 2003 Frequency of diagnostic dilemmas in 131I whole body scanning Nuklearmedizin 42 2 55 62 12695787 1:CAS:528: DC%2BD3sXktF2gur4%3D (Pubitemid 36396046)
49. M Urhan S Dadparvar A Mavi M Houseni W Chamroonrat A Alavi, et al. 2007 Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement Eur J Nucl Med Mol Imaging 34 7 1012 1017 17256140 10.1007/s00259-006-0341-x 1:CAS:528:DC%2BD2sXmtl2jt7k%3D (Pubitemid 46919552)
50. SB Abdul-Fatah M Zamburlini SG Halders B Brans GJ Teule GJ Kemerink 2009 Identification of a shine-through artifact in the trachea with (124)I PET/CT J Nucl Med 50 6 909 911 19470851 10.2967/jnumed.108.060442
51. Stewart BW, Kleihues P. Thyroid cancer. In: Stewart BW, Kleihues P, editors. World cancer report. Lyon, France: Lyon. IARC Press; 2003. p. 257-60.
52. JP Massin JC Savoie H Garnier G Guiraudon FA Leger F Bacourt 1984 Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment Cancer 53 982 992 6692296 10.1002/1097-0142(19840215)53:4<982::AID-CNCR2820530427>3.0.CO;2-E 1:STN:280:DyaL2c7gs1ehtw%3D%3D (Pubitemid 14183762)
53. D Casara D Rubello G Saladini, et al. 1993 Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables J Nucl Med 34 1626 1631 8410272 1:STN:280:DyaK2c%2FhsFCjuw%3D%3D (Pubitemid 23295368)
54. JC Sisson TJ Giordano DA Jamadar, et al. 1996 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma Cancer 78 2184 2192 8918413 10.1002/(SICI)1097-0142(19961115)78:10<2184::AID- CNCR21>3.0.CO;2-U 1:STN:280:DyaK2s%2Fns1Sqsg%3D%3D (Pubitemid 26367613)
55. JS Brink JA Heerden B McIver, et al. 2000 Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis Surgery 128 881 887 11114619 10.1067/msy.2000.109728 1:STN:280:DC%2BD3M%2FnsFegtA%3D%3D
56. JC Sisson DA Jamadar EA Kazerooni, et al. 1998 Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid 8 215 221 9545107 10.1089/thy.1998.8.215 1:STN:280:DyaK1c3gsVKlug%3D%3D (Pubitemid 28145184)
57. S Ilgan O Karacalioglu Y Pabuscu, et al. 2004 Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma Eur J Nucl Med Mol Imaging 31 825 830 14762699 10.1007/s00259-004-1460-x 1:CAS:528:DC%2BD2cXksVensLo%3D (Pubitemid 38758352)
58. LS Freudenberg W Jentzen SP Müller A Bockisch 2008 Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET Eur J Nucl Med Mol Imaging 35 3 502 508 18026950 10.1007/s00259-007- 0601-4 1:CAS:528:DC%2BD1cXjvFOgt7k%3D
59. M Dietlein S Busemeyer C Kobe M Schmidt P Theissen H Schicha 2008 Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma Nuklearmedizin 49 6 216 224 10.3413/nukmed-0321-1005
60. BR Haugen F Pacini C Reiners M Schlumberger PW Ladenson SI Sherman, et al. 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer J Clin Endocrinol Metab 84 3877 3885 10566623 10.1210/jc.84.11.3877 1:CAS:528:DyaK1MXntlOqt74%3D (Pubitemid 30644169)
61. F Pacini PW Ladenson M Schlumberger A Driedger M Luster RT Kloos, et al. 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study J Clin Endocrinol Metab 91 926 932 16384850 10.1210/jc.2005-1651 1:CAS:528:DC%2BD28Xis1CmtL8%3D (Pubitemid 43357760)
62. P Zanotti-Fregonara E Hindié 2010 On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer Eur J Nucl Med Mol Imaging 37 12 2264 2266 20821206 10.1007/s00259-010-1608-9
63. G Schmitz L Fuzesi J Struck, et al. 2005 Expression of the sodium iodide symporter in differentiated thyroid cancer: clinical evidence Nuklearmedizin 44 86 93 15968416 1:CAS:528:DC%2BD2MXpsVartr4%3D (Pubitemid 40827222)
64. MA Walter CP Turtschi C Schindler, et al. 2007 The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study J Nucl Med 48 1620 1625 17873131 10.2967/jnumed.107. 042192 (Pubitemid 47572709)
65. W Jentzen D Balschuweit J Schmitz L Freudenberg E Eising T Hilbel, et al. 2010 The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124)I PET(/CT) imaging Eur J Nucl Med Mol Imaging 37 2298 2306 20625723 10.1007/s00259-010-1532-z 1:CAS:528:DC%2BC3cXhtl2isrjL
66. W Jentzen RF Hobbs A Stahl J Knust G Sgouros A Bockisch 2010 Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer Eur J Nucl Med Mol Imaging 37 5 884 895 20069293 10.1007/s00259-009-1351-2 1:CAS:528:DC%2BC3cXkslakt7Y%3D
67. W Jentzen E Schneider L Freudenberg EG Eising R Görges SP Müller, et al. 2006 Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer Nucl Med Commun 27 8 669 676 16829767 10.1097/00006231-200608000-00009 1:CAS:528:DC%2BD28Xms1ykt7Y%3D (Pubitemid 44305307)